POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy

POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy

ObjectiveAlthough Polymerase-epsilon (POLE)-mutated and mismatch repair (MMR)-deficient endometrial cancers (ECs) are considered as promising candidates for anti-PD-1/PD-L1 therapy, selecting only these patients may exclude other patients who could potentially respond to this treatment strategy, hig...

Full description

Bibliographic Details
Main Authors: Dandan Dong, Huajiang Lei, Duanya Liu, Hansong Bai, Yue Yang, Baijie Tang, Ke Li, Juan Liu, Gang Xu, Xue Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
endometrial cancer
mismatch repair deficiency
immunotherapy
POLE
PD-1
PD-L1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.640018/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.640018/full

Similar Items